Review Article

ECG Markers of Cardiovascular Toxicity in Adult and Pediatric Cancer Treatment

Ștefan Spînu, Gabriel Cismaru, Paul-Mihai Boarescu, Sabina Istratoaie, Alina Gabriela Negru, Cecilia Lazea, Simona Sorana Căinap, Daniela Iacob, Alin Ionut Grosu, George Saraci, Claudia Burz, and Andrei Cosmin Cismaru

1Oncology Institute “Prof. Dr. Ion Chiricuță”, Cluj-Napoca, Romania
2Doctoral School, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
35th Department of Internal Medicine, Cardiology Rehabilitation, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
4Department of Pathophysiology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
5Department of Pharmacology, Toxicology and Clinical Pharmacology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
6“Victor Babes” University of Medicine and Pharmacy, Timișoara, Romania
71st Pediatric Clinic, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
82nd Pediatric Clinic, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
93rd Pediatric Clinic, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
10Cardiology Department, Municipal Clinical Hospital, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
11“Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
12Department of Immunology and Allergology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
13Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

Correspondence should be addressed to Gabriel Cismaru; gabi_cismaru@yahoo.com

Received 30 October 2020; Revised 20 December 2020; Accepted 7 January 2021; Published 19 January 2021

Academic Editor: Anca Daniela Farcaș

Copyright © 2021 Ștefan Spînu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

When a cardiologist is asked to evaluate the cardiac toxic effects of chemotherapy, he/she can use several tools: ECG, echocardiography, coronary angiography, ventriculography, and cardiac MRI. Of all these, the fastest and easiest to use is the ECG, which can provide information on the occurrence of cardiac toxic effects and can show early signs of subclinical cardiac damage. These warning signs are the most desired to be recognized by the cardiologist, because the dose of chemotherapeutics can be adjusted so that the clinical side effects do not occur, or the therapy can be stopped in time, before irreversible side effects. This review addresses the problem of early detection of cardiotoxicity in adult and pediatric cancer treatment, by using simple ECG recordings.

1. Introduction

In the last twenty years, the survival and life expectancy of adults and children with cancer have risen significantly, mainly due to the new chemotherapy. However, chemotherapeutic agents have secondary and adverse effects, some of them dreadful. Their early recognition can prevent the development of associated sometimes fatal pathologies. Monitoring
the cardiac side effects of chemotherapy is feasible generally using echocardiography, radionuclide ventriculography, dosing cardiac biomarkers [1] such as BNP and NT-proBNP [2], and ECG. Sometimes, these techniques may identify subclinical heart damage [3] before the clinical manifestation by heart failure, chronic coronary syndrome, or myocardial infarction. Therefore, an attempt was made to discover early markers of toxicity, and the purpose of this review is to present published data on ECG changes as markers of cardiac toxicity caused by chemotherapeutics. The 12-lead surface ECG is a simple examination that is performed quickly in about 3 minutes and can provide information on cardiotoxicity, which is mainly manifested by ischemic changes or by arrhythmias. Of course, there are more subtle changes, which can precede the installation of arrhythmias: for example, bifid and broad P wave lasting more than 120 ms that precedes the installation of atrial fibrillation or the prolonged QT interval > 500 ms that precedes in some cases the installation of torsade de points. Sometimes, the presence of multiple atrial ectopic beats may require stopping chemotherapy in order to prevent atrial fibrillation; the presence of numerous PVCs with multiple morphologies may require discontinuation of chemotherapy due to an increased risk of malignant ventricular arrhythmias such as polymorphic ventricular tachycardia or ventricular fibrillation. These ECG markers are easily recognizable by the clinical cardiologist or interventional arrhythmologist but are more challenging for an oncologist or general practitioner. The ECG does involve not only 12-lead recording but also derivatives such as recording with a monitor during hospitalization, single-lead or two-lead monitoring at home with a portable monitor (Omron, Heal Force Print 180 D, 180B), and monitoring by Apple devices, smartwatch, smartphones, Holter ECG/24 hours, exercise stress test, or electrophysiological study [4]. These are derivatives of the 12-lead ECG, and we will not refer to them in this review. The electrocardiographic changes given by chemotherapy can be transient, and therefore, other methods than the standard ECG are used to detect them. Generally, before starting chemotherapy, it is suitable for the patient to have a baseline ECG recording so that later, after starting the treatment, the measurements may be compared with the initial recording.

2. Arrhythmogenic Mechanisms of Chemotherapy

There are several mechanisms by which chemotherapy can become proarrhythmogenic (Table 1):

(1) By the effect of direct damage to the myocardial cell with the release of natriuretic peptides BNP, NT-proBNP, and troponin, with the development of ischemic or nonischemic dilated cardiomyopathy, increased left ventricular filling pressures, and subsequently left atrial and fibrillation

(2) Coronary spasm with the induction of myocardial ischemia or a direct effect of the chemotherapeutic on coronary vascularization with secondary ische-

mia, with or without myocardial necrosis and arrhythmogenesis by the formation of abnormal reentry circuits or abnormal depolarizations

(3) Action at the level of ion channels with impaired ventricular depolarization or repolarization, prolongation of the QT interval, and induction of polymorphic ventricular tachycardia (torsade de pointes)

(4) Direct action on the conduction system: sinus node, atrioventricular node, His, left or right branch, respectively, and Purkinje network

One of the most common side effects of chemotherapy that can be detected on the ECG in 12 leads is sinus bradycardia. Taxanes and angiogenesis inhibitors (thalidomide) can cause sinus bradycardia, most likely through a direct action on the sinus node. Nevertheless, taxanes can have effects at other levels of the atrioventricular conduction system. Thus, paclitaxel can affect the infranodal conduction system (after the bifurcation of the His) and lead to the appearance of the right or left branch block. If the lesion is located at the supraneural level, atrioventricular blocks of varying degrees, from 1 to 3, may occur. The conduction disorders generally occur within 4 hours of initiating the paclitaxel infusion and disappear after stopping the chemotherapeutic, usually within the first 48 hours [5]. The mechanism by which paclitaxel affects the conduction system is either directly by affecting the sinus node, atrioventricular node, and His-Purkinje system or indirectly by affecting the parasymptathetic nervous system, which induces bradycardia or conduction disorders. Thalidomide-induced sinus bradycardia is also explained by the action on the sympathetic nervous system [6] and also the induction of a manifest clinical or subclinical hypothyroidism which is in turn associated with sinus bradycardia by intrinsic remodeling of the sinus node [7]. On the other hand, thalidomide has also been implicated in the development of rapid ventricular arrhythmias, especially ventricular tachycardia [8].

Another mechanism promoting cardiac arrhythmias is through myocardial ischemia [9] or even necrosis if myocardial ischemia persists for a long time. Thus, alkylating agents cisplatin, cyclophosphamide [10], ifosfamide, and melphalan may promote coronary vasospasm, cardiomyocyte damage, and endothelial damage. Up to 10% of cisplatin users develop atrial and ventricular arrhythmias within the first 24 hours-3 days of initiating treatment, with the disappearance of these side effects within approximately 1 week. Melphalan has also been implicated in the genesis of episodes of atrial fibrillation or atrial flutter [11].

Anthracycines cause atrial and ventricular arrhythmias by inducing structural cardiomyopathy associated with decreased left ventricular systolic function with altered ejection fraction. This decrease in ejection fraction leads to increased left ventricular end-diastolic pressure and increased left intra-atrial pressure and favours atrial arrhythmias such as extrasystoles, atrial tachycardia, or atrial fibrillation. On the other hand, the marked decrease of the ejection fraction may favour ventricular arrhythmias: premature ventricular contractions, ventricular tachycardia, and ventricular fibrillation.
5-Fluorouracil validates its arrhythmogenic effects through coronary vasospasm and the myocardial ischemia it induces. Like 5-FU, interleukin-2 promotes arrhythmias by inducing vasospasm with consequent prolonged myocardial ischemia (myocarditis) [12].

3. ECG Modifications and Arrhythmias Induced by Different Chemotherapeutics

3.1. Anthracyclines. Anthracyclines are currently used to treat leukemias, lymphomas, breast cancer, and solid pediatric tumors. Generation I anthracyclines (daunorubicin and doxorubicin) have as a side effect the irreversible development of nonischemic dilated cardiomyopathy, and their effects are cumulated with increasing doses and duration of use (an incidence of 5-8% is observed at a cumulative dose of 450 mg/m²) [13].

A study by Kilickap’s team that involved Holter EKG monitoring for 48 hours of patients immediately after doxorubicin infusion showed a paroxysmal atrial fibrillation rate of 10.3% [14]. However, when ECG monitoring was performed at each visit for the continuation of chemotherapy, a 6% incidence of this arrhythmia was recorded [15]. The highest detection rate (56.6%) was objectified by interrogating the implantable defibrillator in patients with cardiac dysfunction associated with chemotherapy [16]. The same study shows that the incidence of nonsustained ventricular tachycardia can reach up to 73.9% of cases, similar to those in the control group, of patients with nonischemic cardiomyopathy, not related to anthracyclines (was not significantly different from non-anthracycline-related cardiomyopathy and dilated cardiomyopathy or ischemic heart disease) [16]. However, premature ventricular contractions remain the most common form of anthracycline-induced ventricular arrhythmia (the number of bigeminal ventricular extrasystoles increased significantly, p < 0.05) [17].

A study analyzing the effects of epirubicin on QTc interval dispersion (defined as the difference between the maximum and minimum QT intervals on the recorded electrocardiogram) showed an increase in this parameter in all patients included in the research. When dexrazoxane was administered in addition to epirubicin, the dispersion of the QT interval decreased statistically (p < 0.05) compared to the group without dexrazoxane [18].

3.2. Alkylating Antineoplastic Agents. Alkylating agents are frequently used before stem or bone marrow transplantation. Several factors increase the risk of developing this melphalan-induced arrhythmia, including advanced age (over 63 years: risk ratio: 4.8 (95% confidence interval (CI) 3.2-7.6), p < 0.001), dilated left atrium over 33 cc/m² (risk ratio: 2 (95% CI 1.3-3.1), p < 0.001), left ventricular systolic dysfunction (p < 0.001), and even cardiac amyloidosis (this was not significant, p = 0.08) [19, 20]. Besides, when a supraventricular arrhythmia occurs after hematopoietic stem cell transplantation, the prognosis of these patients worsens as observed in a study conducted by Tonorezos et al. on a group of 1177 patients. Of these, those with atrial fibrillation or flutter had...
a higher risk of in-hospital death (28% vs. 3%, p < 0.001) and also one year after the intervention (41% vs. 15%; p < 0.001). Practically, the existence of arrhythmias in post-stem cell transplant patients has been an independent predictor of mortality with a greater risk for death within a year of transplant (odds ratio 3.5 (95% CI 2.1-5.9; p < 0.001)) [21].

Busulfan is another chemotherapeutic belonging to the alkylating agent class. The incidence of developing atrial fibrillation was up to 6.4% when used in combination with cyclophosphamide [22].

In conclusion, during treatment with alkylating agents, patients should be monitored for atrial fibrillation with melphalan and busulfan and also for the development of structural abnormalities that may be responsible for ventricular arrhythmias with cyclophosphamide and ifosfamide.

3.3. Anti-HER2 Agents. An analysis that included over 8000 patients treated with trastuzumab reported an incidence of atrial fibrillation of 1.2% after trastuzumab use (95% CI 0.56-2.68) [23]. On the other hand, a study published in 2015 by Pivot and colleagues compared the cardiac toxicity generated by trastuzumab after 6 months and 12 months of adjuvant treatment, respectively. Of the 3380 enrolled patients, only 0.65% had NYHA III/IV heart failure classes in the one-year treatment arm and 0.53% in the six-month treatment arm, with no statistically significant difference between the two groups. For NYHA I/II heart failure classes, the number of cases was significantly higher in the one-year treatment group (5.9%) than in the group receiving 6 months of treatment (3.4%) [24]. When trastuzumab was used after a “dose-dense” (accelerated) regimen of anthracyclines and taxanes, the enrolled patients showed a significant decrease in LVEF in a tiny percentage (1%) [25].

The use of trastuzumab with paclitaxel after an anthracycline and cyclophosphamide induction regimen resulted in symptomatic heart failure in 4% of patients enrolled in the study (95% CI 0.5-13.2), and in 21% of them, a decrease in LVEF below 50% was noticed (95% CI 11.1-34.7) [26].

Another study that evaluated the safety of administration of trastuzumab in the elderly found that of the 22 patients, only 2 had a 10% asymptomatic decrease in LVEF [27].

More extensive studies of approximately 45,000 women with a mean age of 76.2 years showed that the 3-year incidence of cardiomyopathy or heart failure of any grade was 32.1% in the trastuzumab-only group and 41.9% in patients who also received anthracyclines compared with no adjuvant therapy (18.1%, p < 0.001) [28].

Trastuzumab-emtansine (T-DM1), a combination used in the second line of treatment after trastuzumab, did not cause any significant cardiovascular events (including symptomatic heart failure) in the 153 patients evaluated in Krop et al.’s study [29].

Lapatinib is a safer product than trastuzumab in that it rarely induces left ventricular dysfunction and arrhythmias [30].

3.4. Tyrosine Kinase Inhibitors. These products do not induce structural abnormalities of the myocardium but may prolong the QT interval and induce ventricular arrhythmias such as torsade de pointes.

Ibrutinib is a Bruton tyrosine kinase inhibitor used in B-line haematological malignancies such as chronic lymphocytic leukemia and mantle cell lymphoma. A study conducted by Yun et al., published in 2017, shows an incidence of atrial fibrillation/flutter of 8.18% in patients treated with ibrutinib compared to placebo (8.18% vs. 0.93%, RR = 8.81, 95% CI 2.70-28.75, p < 0.001). It should be remembered that the risk of arrhythmia is proportional to the dose and time of treatment [31]. According to the HELIOS phase 3 trial published in 2018 in the Leukemia journal, the rate of occurrence of atrial fibrillation/flutter as an adverse event was reported at 4.9% [32]. Another study, published in the NEJM, showed similar incidences of atrial fibrillation of 6%. In 25% of the patients, it was necessary to stop the treatment, but for the rest, no intervention was needed [33]. Although ibrutinib carries a relatively high risk of atrial fibrillation, it also acts as an antiplatelet agent, associated with an increased risk of bleeding. Therefore, the use of antivitamin K in this category of patients has been discouraged. It seems that the new oral anticoagulants such as dabigatran, rivaroxaban, or apixaban have a higher safety profile [34].

Regarding Bruton tyrosine kinase inhibitors inducing ventricular arrhythmias, there is a reported incidence of 678 events/100,000 patients. Surprisingly, ibrutinib does not prolong the QTc interval; it even shortens it, although it does induce a risk of ventricular tachycardia [35].

3.5. Antimicrotubule Agents. In a study conducted by Rowinsky et al., 2 of the 140 patients treated with paclitaxel had a high-grade atrioventricular block and therefore required the implantation of a pacemaker. However, EKG monitoring of patients during injection is not indicated [36].

3.6. Immunomodulating Agents. Thalidomide is an agent used in the treatment of multiple myeloma that can cause bradyarrhythmias, including different types of atrioventricular block, both alone and in combination with other chemotheperapeutics. Sinus bradycardia has been reported in 26% up to 53% of patients and most often resolves within 12-21 days of discontinuation of treatment [7].

Thalidomide was also associated with atrial fibrillation, with an incidence of 4.7% versus 3.4% in the placebo-treated arm. Therefore, cardiac monitoring is recommended in all patients treated with this immunomodulator [37].

Lenalidomide is another immunomodulator used in both multiple myeloma and myelodysplastic syndrome. It can induce supraventricular arrhythmias with an incidence ranging from 4.6 to 7% when used in combination with dexamethasone [38].

3.7. Amsacrine. This substance is used for the treatment of acute myeloid leukemia and electrophysiologicaly acts similar to anthracyclines. It can cause atrial and ventricular arrhythmias, respectively, and QT prolongation. However, proarrhythmic effects are rare and were reported in 0.7% in a study of 5340 patients [39]. The administration of amsacrine...
is prone to hydroelectrolytic disturbances which may eventually lead to arrhythmias. Therefore, the use of this chemotherapeutic requires strict monitoring of the electrolytes (especially the level of potassium) to be administered safely, even in patients with left ventricular dysfunction [40].

3.11. Antimetabolites. The most common side effects include cardiac arrhythmias, increased capillary permeability with tissue extravasation and hypotension and tachycardia. If those modifications occur in a structurally normal heart, they are not arrhythmogenic, but when they occur in an ischemic heart, they can produce atrial and ventricular arrhythmias. Another speculated mechanism is the action that different vasopressors have on the electrical system of the heart. Ventricular arrhythmias are also possible, but the frequency of life-threatening ventricular tachycardias is low, between 0.4 and 1.1% [41].

3.9. Trisenox (Arsenic Trioxide). Arsenic trioxide inhibits fast and slow potassium channels and activates ATP-dependent potassium channels. This is the electrophysiological mechanism underlying QT prolongation with a high risk of torsade de pointes. Approximately 38% of patients who are treated with arsenic trioxide develop QT prolongation > 450 ms and 27% > 500 ms [42]. The degree of QT prolongation was higher in male patients during the first cycle of treatment and also in patients with hypokalemia regardless of gender. Corrected QT intervals in these patients normalized up to the second cycle of chemotherapy, so it was considered that arsenic trioxide did not cause a permanent prolongation of the QTc interval [42]. Because life-threatening arrhythmias are rarely associated with arsenic trioxide, caution is advised in the use of QTc with the Bazett formula since the risk of cardiac toxicity may sometimes be overestimated, and therefore, cancer treatment may be unnecessarily discontinued. In these situations, alternative correction formulas are recommended [43]. Fortunately, the doses used in practice at this time are optimized so that ventricular arrhythmias occur with a fair frequency, but it is still necessary to monitor electrolytes and ECG in those patients, both before and during treatment [44].

3.10. Histone Deacetylase Inhibitors. These products, which are used to treat cutaneous T-cell lymphoma and multiple myeloma, can prolong the QT interval, and there have been reported cases of sudden death after starting treatment. For these reasons, they are contraindicated in the case of a QT interval over 450 ms. The underlying mechanism of arrhythmogenesis is not fully understood. However, it is currently accepted that these inhibitors interact with potassium hERG channels [45].

3.11. Antimetabolites. The most common side effects with 5-fluorouracil and capcitabine are chest pain, with or without EKG signs of ischemia. The mechanism of action is a coronary spasm. A spasm was demonstrated by reproduction in the radial artery after administration of 5-fluorouracil. The use of calcium channel blockers and long-acting nitrates has been proposed to counteract the vasospastic effects of antimetabolites [46].

4. Arrhythmias Determined by Long QT Interval

One of the most straightforward cardiotoxicity markers that can be measured on the surface ECG is the QT interval (Figure 1), an easy to measure, standardized interval, the most used method being the tangent method in derivation II or V5. Because ECG paper is often marked with lines or squares delimiting 40 ms, the measurement is easy considering the number of squares found along the length of the QRS complex and the T-wave. This interval represents depolarization along with ventricular repolarization. The QT interval measurement must not include the U-wave unless there is an evident fusion between T and U.

This QT interval is vital in arrhythmogenesis because when prolonged, it can be associated with polymorphic ventricular tachycardia, in this case called torsade de pointes. Not all polymorphic tachycardia is torsade de pointes but only that which is accompanied by an extended QT interval. In other cases, the term “torsade-like” can be used.

Due to the fact that the QT interval can be longer in the case of bradycardia and shorter in the case of tachycardia, there are mathematical formulas for correcting the QT interval depending on the frequency: Bazett, Fridericia, Framingham, and Hodges. It is considered that a corrected QT interval < 450 ms in men and <460 ms in women is normal. When the QT interval is >500 ms, the risk for torsade de pointes is high. Intervals between 450 and 500 ms considered the “grey area” should be monitored by serial recordings, and serum electrolytes should be checked for hypokalemia or hypomagnesemia.

The 450 ms limit of the QT interval is considered too restrictive in cancer patients because if this limit was to apply, then over 10% of patients receiving chemotherapy would have to give up perhaps life-saving therapy [47]. On the other hand, in oncology patients, there have been found variations of the QT interval up to 60 ms within 24 hours. Thus, in cancer patients, a prolonged QT interval > 480 ms or an increase of >100 ms after the initiation of chemotherapy is considered significant [48, 49].

Cancer patients who are treated with antiarrhythmic medication for heart disease are at risk of developing drug interactions with the possibility of prolonging the QT interval. Class IA (quinidine and procainamide) and class III antiarrhythmics (amiodarone and sotalol) prolong the QT interval by their particular mechanism of action on ion channels. On the other hand, antiemetic drugs such as ondansetron and droperidol also prolong the QT interval. Among analgesics, methadone, an opioid derivative, also prolongs the QT interval (+14.1 msec, p < 0.001) [50]. Commonly used antineoplastic medication may also have the effect of prolonging the QT interval: tyrosine kinase inhibitors (rituximab, dasatinib, lapatinib, nilotinib, and sorafenib), anthracyclines (doxorubicin and daunorubicin), and antimetabolites (capcitabine, panobinostat, romidepsin, and vorinostat). These associations with antiarrhythmics should be avoided to prevent malignant ventricular arrhythmias such as torsade de pointes [51].

Arsenic trioxide is known to prolong the QT interval, which is why therapy should be stopped if the interval is
prolonged >500 ms. When the interval decreases to 460 ms, the treatment can be resumed. Shen et al. [52], Niu et al. [53], and Unnikrishnan et al. [54] have published case reports of torsade de pointes in patients being treated with arsenic trioxide. However, there is also stronger evidence than isolated published cases. Thus, Ohnishi et al. [55] reported 8 cases of QT prolongation after arsenic trioxide infusion, but none of the 8 patients showed torsade de pointes. The most extensive patient studies of arsenic trioxide included approximately 100 patients. Thus, the study of Bey et al. [42] on 99 patients observed QT prolongation over 500 ms in 26% of individuals. Only one of these patients had torsade de pointes, but it was also associated with hypokalemia. Also, Roboz et al. [43] in a group of 113 patients observed QT prolongation >500 ms in 12% of individuals, and none of them showed torsade de pointes.

4.1. Tyrosine Kinase Inhibitors. Nilotinib was associated with 5 to 15 ms QT prolongation, but this prolongation was not associated with polymorphic ventricular tachycardia [56]. On the other hand, in the study of Tam et al. [57], nilotinib administered to healthy volunteers resulted in an average QT prolongation of 18 ms. On subgroup analysis, 1.9% and even 2.5% of patients with chronic myeloid leukemia presented QT prolongation. Of all patients treated with nilotinib from Tam et al.’s study, 0.3% died suddenly, and it was assumed that QT interval prolongation had an involvement, although no direct relationship between had been demonstrated. Lu et al. [58]. have also shown that dasatinib, sunitinib, and nilotinib can prolong the QT interval. Studies with Vandetanib have shown a QT prolongation in 9% to 61% of the patients [59]. In Wells et al.’s [60] and Natale et al.’s [61] studies, QT prolongation occurred in approximately 5.1% of patients; only one of the patients presented torsade de pointes; in all other patients, the QT prolongation had no arrhythmic consequence. In these 2 studies that we have mentioned, the definition of the prolonged QT interval was >550 ms or an increase of >100 ms between 2 consecutive measurements. Zang et al. [62], performed a systematic review and meta-analysis of Vandetanib studies related to QT prolongation. They showed that QT prolongation > 450 /460 ms occurred in 16.4% (95% CI 8.1–30.4) of patients and >500 ms prolongation occurred in 3.7% of patients (95% CI 1.7–7.8).

4.2. Histone Deacetylation Inhibitors. Vorinostat has been incriminated in the prolongation of the QT interval complicated with polymorphic ventricular tachycardia in a case report published by Lynch et al. [63]. It is important to mention that the patient associated hypokalemia. Probably hypokalemia, more than chemotherapy, was involved in the development of malignant ventricular arrhythmias, and this patient would have had a congenital long QT syndrome that could have been exposed by vorinostat. However, no genetic study has been done to confirm this hypothesis. Romidepsin has been incriminated in several cases of sudden cardiac death, but there has been no clear relationship between QT prolongation and death, as patients did not have an ECG recording before death [64, 65]. In the study of Piekarz et al. [64], QT prolongation was approximately 15 ms after administration of romidepsin. This prolongation is insignificant and does not justify stopping chemotherapy that might be life-saving. Last but not least, panobinostat is another histone deacetylation inhibitor, which has also been shown to prolong the QT interval up to 20 ms [65]. In conclusion, histone deacetylation inhibitors may prolong the QT interval, but no clear association with arrhythmic events such as torsade de pointes has been demonstrated.

4.3. Anthracyclines. Even though the most common side effect of anthracyclines is structural impairment of the left ventricle with decreased LV ejection fraction, to a lesser extent, anthracyclines may alter the QT interval. In the study of Galetta et al. [18], epirubicin produced variable QT prolongation when administered to patients with non-Hodgkin’s lymphoma (all the patients showed increased
QT dispersion (44.3 ± 8.4 vs. 68.4 ± 11.4 ms, p < 0.001) and QTc dispersion (46.2 ± 6.2 vs. 72.42 ± 8.4 ms, p < 0.001) after epirubicin-based chemotherapy in non-Hodgkin lymphoma patients). Also, in the study of Nousiainen et al. [66], QTc dispersion increased from 26.5 ± 2.5 to 39.0 ± 3.5 ms (p = 0.039). Five patients (18%) developed QT dispersion exceeding 50 ms. At the same time, Liu et al. [67] showed in experimental studies on rabbit myocytes that tamoxifen can prolong the QT interval.

5. ECG Changes Produced by Chemotherapy in Children

As in adults, chemotherapy can have cardiac toxicity in children. But children have 2 particularities: First, their heart is constantly developing, and the structure that has been affected by chemotherapy will increase with the growth of the child’s heart, so in the following years, the injured structure will become larger [68]. Second, the survival of children is generally higher than that of adults; therefore, on the one hand, it is important to limit the cardiac toxic effect of chemotherapy which will last for years; on the other hand, if the toxic effect occurred, the evolution of left ventricular dysfunction should be blocked to prevent the development of clinical manifest heart failure. As for arrhythmias, they generally appear in the acute phase and disappear after stopping the chemotherapeutic. If arrhythmias occur in the chronic, postadministration phase, then antiarrhythmic drugs are generally needed to control arrhythmias.

Up to 25% of children who are treated with anthracyclines may have electrocardiogram changes [69]. These can be QT interval prolongation, ischemic or nonischemic T-wave and ST segment changes, bundle branch blocks or atrioventricular blocks, decreased QRS complex amplitude, and electric axis change. In addition, atrial or ventricular arrhythmias with different severity ranging from premature contractions to tachycardia were described. In the study of Larsen et al. [70] performed on 100 children with an average age of 15 years, 73 treated with anthracyclines and 27 treated with anthracyclines plus radiotherapy, minor arrhythmias were detected, such as rare atrial or ventricular premature contractions, as well as major arrhythmias. Among these are sustained supraventricular tachycardia or ventricular tachycardia that occurred especially at high doses of anthracyclines > 200 mg/m². Furthermore, prolonged QT interval > 480 ms was found in approximately 14% of children. Another study by Steinherz and Steinherz [71] on 100 children identified ECG changes in 13 of them after anthracyclines. One of the 100 died suddenly, without any ECG changes, and 2 died due to arrhythmias. In another study, Lipshtultz et al. [72] found 5% nonsustained ventricular tachycardia in children treated with doxorubicin. Amsacrine [73] can also cause ECG changes in children and usually occur within the first minutes or hours of administration. These are QT prolongations, ST and T-wave ischemic changes or nonspecific nonischemic changes, and atrial or ventricular tachyarrhythmias. Usually, these changes occur from the first dose and can be quickly detected by ECG. If the patient has an underlying hypokalemia, then the depolarization and repolarization changes given by amsacrine may be exacerbated by hypokalemia, so serum potassium levels should be monitored during therapy.

Massin et al. [74] studied severe arrhythmias that occur in the first 24 hours in 33 children with various tumors treated with chemotherapy. Two patients developed sinoatrial block or atrioventricular block during the first 4 hours of daunorubicin infusion, 8 children had atrial and ventricular premature beats or bursts of premature beats during the combination of vincristine+daunorubicin or vincristine+cyclophosphamide, and none of the children presented life-threatening arrhythmias.

In a study by Mulrooney et al. [75], 2715 children who survived neoplastic disease have been checked for ECG changes, which were interpreted as chronic side effects due to chemotherapy. Thus, 99 individuals were identified with pathological Q-waves as signs of old myocardial infarction, 5 with left branch block, 13 with right branch block, 4 with bifascicular block, 8 with significant QT prolongation, and none with atrial flutter or atrial fibrillation. In total, major ECG changes were present in 290 of 2715 patients (approximately 10%) and minor ECG changes in 565 (23.3%). Minor changes included atrial or ventricular premature beats, nonspecific T-wave or ST segment changes, low QRS, and deviation of the heart’s electrical axis.

Newer studies are trying to determine whether lower chemotherapy doses that do not induce ECG changes still remain effective for the suppression of neoplastic disease. Researchers are trying to verify if lower doses that do not cause an excessive increase in QT interval > 480 ms or that produce only benign atrial or ventricular premature beats are still effective in controlling the child’s neoplastic disease. The results of the studies would further benefit children, as toxic effects might affect a developing, immature heart.

6. Conclusions

Oncological treatment requires a good collaboration between the oncologist and the cardiologist. Even if new drugs increase the life expectancy of cancer patients, death may be due to a therapeutic dosing error, due to proarhythmic side effects, or due to impaired left ventricular ejection fraction. For these reasons, some oncology clinics have hired a cardiologist who can monitor the evolution of heart function during chemotherapy by ECG, Holter ECG, and echocardiography. The cardiologist must know the limits that are acceptable for subclinical cardiac toxicity such as a mild but reasonably prolonged QT interval below 480 ms, the presence of benign arrhythmias such as atrial or ventricular premature beats, the presence of insignificant ST segment and T-wave changes, and changes in the heart axis. All of these ECG insignificant changes should not stop the child or adult from receiving a potentially life-saving therapy. When the oncology-cardiologist is not available, close collaboration with a cardiology clinic or outpatient cardiac clinic with experienced physicians in monitoring toxic effects of chemotherapy is required.
Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] L. L. Tan and A. R. Lyon, “Role of biomarkers in prediction of cardiotoxicity during cancer treatment,” Current Treatment Options in Cardiovascular Medicine, vol. 20, no. 7, 2018.

[2] D. Raluca Maniu, C. Blag, G. Popa et al., “The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia,” JOURNAL OF BUON, vol. 23, no. 7, pp. 122–131, 2018.

[3] M. Mocan, L. D. Mocan Hognog, F. P. Anton et al., “Biomarkers of inflammation in left ventricular diastolic dysfunction,” Disease Markers, vol. 2019, Article ID 7583690, 14 pages, 2019.

[4] L. Muresan, G. Cismaru, R. P. Martins et al., “Recommendations for the use of electrophysiological study: update 2018,” Hellenic Journal of Cardiology, vol. 60, no. 2, pp. 82–100, 2019.

[5] E. K. Rowinsky, E. A. Eisenhauer, V. Chaudhry, S. G. Arbuck, and R. C. Donohower, “Clinical toxicities encountered with paclitaxel (Taxol),” Seminars in Oncology, vol. 20, 4 Supplement 3, pp. 1–15, 1993.

[6] B. Barloge, G. Tricot, E. Anaisse et al., “Thalidomide and hematopoietic-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 354, no. 10, pp. 1021–1030, 2006.

[7] I. E. Fahdi, V. Gaddam, J. F. Saucedo et al., “Bradycardia during therapy for multiple myeloma with thalidomide,” The American Journal of Cardiology, vol. 93, no. 8, pp. 1052–1055, 2004.

[8] S. Ballanti, E. Mastrodicasa, N. Bolli et al., “Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia,” Nature Clinical Practice. Oncology, vol. 4, no. 12, pp. 722–725, 2007.

[9] J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry, “Cardiotoxicity of cancer therapy,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 7685–7696, 2005.

[10] J. S. Gottsdiener, F. R. Appelbaum, V. J. Ferrans, A. Deisseroth, and J. Ziegler, “Cardiotoxicity associated with high-dose cyclophosphamide therapy,” Archives of Internal Medicine, vol. 141, no. 6, pp. 758–763, 1981.

[11] V. Feliz, S. Saiyad, S. M. Ramarao, H. Khan, F. Leonelli, and M. Guglin, “Melphalan-induced supraventricular tachycardia: incidence and risk factors,” Clinical Cardiology, vol. 34, no. 6, pp. 356–359, 2011.

[12] M. de Forni, M. C. Malet-Martino, P. Jaillais et al., “Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study,” Journal of Clinical Oncology, vol. 10, no. 11, pp. 1795–1801, 1992.

[13] Doxorubicin, “FDA package insert,” https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/062921s022lbl.pdf.

[14] S. Killick, I. Barista, E. Akgul, K. Aytemir, S. Aksoy, and G. Tekuzman, “Early and late arrhythmogenic effects of doxorubicin,” Southern Medical Journal, vol. 100, no. 3, pp. 262–265, 2007.

[15] M. Amioka, A. Sairaku, T. Ochi et al., “Prognostic significance of new-onset atrial fibrillation in patients with non-Hodgkin’s lymphoma treated with anthracyclines,” The American Journal of Cardiology, vol. 118, no. 9, pp. 1386–1389, 2016.

[16] M. Mazur, F. Wang, D. O. Hodge et al., “Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy,” JACC: Clinical Electrophysiology, vol. 3, no. 2, pp. 139–150, 2017.

[17] N. K. Raabe and L. Storstein, “Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration an evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring,” Acta Oncologica, vol. 30, no. 7, pp. 843–846, 1991.

[18] F. Galetta, F. Franzoni, G. Cervetti et al., “Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients,” Biomedicine & Pharmacotherapy, vol. 59, no. 10, pp. 541–544, 2005.

[19] A. Singla, W. J. Hogan, S. M. Ansell et al., “Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 19, no. 8, pp. 1233–1237, 2013.

[20] S. Longhi, C. C. Quarta, A. Milandri et al., “Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role,” Amyloid, vol. 22, no. 3, pp. 147–155, 2015.

[21] E. S. Tonorezos, E. E. Stillwell, J. J. Calloway et al., “Arrhythmias in the setting of hematopoietic cell transplants,” Bone Marrow Transplantation, vol. 50, no. 9, pp. 1212–1216, 2015.

[22] M. Ulrickson, J. Aldridge, H. T. Kim et al., “Busulfan and cyclophosphamide (BuCy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single- institution experience,” Biology of Blood and Marrow Transplantation, vol. 15, no. 11, pp. 1447–1454, 2009.

[23] M. Yuan, G. Tse, Z. Zhang et al., “The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta-analysis,” Cardiovascular Therapeutics, vol. 36, no. 6, Article ID e12475, 2018.

[24] X. Pivot, T. Suter, J. M. Nabholtz et al., “Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study,” European Journal of Cancer, vol. 51, no. 13, pp. 1660–1666, 2015.

[25] C. Dang, M. Fornier, S. Sugarman et al., “The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1216–1222, 2008.

[26] H. Kelly, G. Kimmick, E. C. Dees et al., “Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide,” Clinical Breast Cancer, vol. 7, no. 3, pp. 237–243, 2006.

[27] L. Militello, P. Carli, S. Spazzapan et al., “Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer,” Journal of Clinical Oncology, vol. 29, supplement 27, p. 282, 2011.

[28] J. Chen, J. B. Long, A. Hurria, C. Owusu, R. M. Steingart, and C. P. Gross, “Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer,” Journal of the American College of Cardiology, vol. 60, no. 24, pp. 2504–2512, 2012.

[29] I. E. Krop, T. M. Suter, C. T. Dang et al., “Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer,” Journal of Clinical Oncology, vol. 33, no. 10, pp. 1136–1142, 2015.
[30] C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capcitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006.

[31] S. Yun, N. D. Vincelette, U. Acharya, and I. Abraham, “Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials,” Clinical Lymphoma Myeloma and Leukemia, vol. 17, no. 1, pp. 31–37.e13, 2017.

[32] G. Fraser, P. Cramer, F. Demirkan et al., “G. Fraser, P. Cramer, F. Demirkan et al.,” [50x620][32] J. A. Burger, A. Tedeschi, P. M. Barr et al., “M. B. Atkins, M. T. Lotze, J. P. Dutcher et al.,” [50x534][35] J. A. Burger, A. Tedeschi, P. M. Barr et al., “A. Guha, M. H. Derbala, Q. Zhao et al.,” [50x388][37] S. V. Rajkumar, L. Rosiñol, M. Hussein et al., “E. K. Rowinsky, W. P. McGuire, T. Guarnieri, J. S. Fisherman, ” [50x323][69x146]ff
cardiac disturbances during the administration of taxol,” Journal of Clinical Oncology, vol. 9, no. 9, pp. 1704–1712, 1991.

[33] J. A. Burger, A. Tedeschi, P. M. Barr et al., “Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 373, no. 25, pp. 2425–2437, 2015.

[34] T. E. Wizcer, L. B. Levine, J. Brumbaugh et al., “Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib,” Blood Advances, vol. 1, no. 20, pp. 1739–1748, 2017.

[35] A. Guha, M. H. Derbala, Q. Zhao et al., “Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies,” Journal of the American College of Cardiology, vol. 72, no. 6, pp. 697–698, 2018.

[36] E. K. Rowinsky, W. P. McGuire, T. Guarnieri, J. S. Fisherman, M. C. Christian, and R. C. Donehower, “Cardiac disturbances during the administration of taxol,” Journal of Clinical Oncology, vol. 9, no. 9, pp. 1704–1712, 1991.

[37] S. V. Rajkumar, L. Rosiñol, M. Hussein et al., “Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2171–2177, 2008.

[38] Lenalidomide, “FDA package insert,” https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021880s049lbl.pdf.

[39] M. Guglin, M. Aljayeh, S. Saiyad, R. Ali, and A. B. Curtis, “Introducing a new entity: chemotherapy-induced arrhythmia,” Europace, vol. 11, no. 12, pp. 1579–1586, 2009.

[40] Z. A. Arlin, E. J. Feldman, A. Mittelman et al., “Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia,” Cancer, vol. 68, no. 6, pp. 1198–1200, 1991.

[41] M. B. Atkins, M. T. Lotze, J. P. Dutcher et al., “High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2105–2116, 1999.

[42] J. T. Barbej, J. C. Pezzullo, and S. L. Soignet, “Effect of arsenic trioxide on QT interval in patients with advanced malignancies,” Journal of Clinical Oncology, vol. 21, no. 19, pp. 3609–3615, 2003.

[43] G. J. Roboz, E. K. Ritchie, R. F. Carlin et al., “Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide,” Journal of Clinical Oncology, vol. 32, no. 33, pp. 3723–3728, 2014.

[44] National Comprehensive Cancer Network, “Acute myeloid leukemia guidelines version 1-2021,” https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.

[45] M. G. Fradley and J. Moslehi, “QT prolongation and oncology drug development,” Cardiac Electrophysiology Clinic, vol. 7, no. 2, pp. 341–355, 2015.

[46] T. Südhoff, M. D. Enderle, M. Pahlke et al., “5-Fluorouracil induces arterial vasoconstrictions,” Annals of Oncology, vol. 15, no. 4, pp. 661–664, 2004.

[47] M. Varterasian, M. Meyer, H. Fingert et al., “Baseline heart rate-corrected QT and eligibility for clinical trials in oncology,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3378–3379, 2003.

[48] A. Naing, H. Veasey-Rodrigues, D. S. Hong et al., “Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs,” Annals of Oncology, vol. 23, no. 11, pp. 2960–2963, 2012.

[49] P. Y. Kim and M. S. Ewer, “Chemotherapy and QT prolongation: overview with clinical perspective,” Current Treatment Options in Cardiovascular Medicine, vol. 16, no. 5, 2014.

[50] M. J. Krantz, C. M. Lowery, B. A. Martell, M. N. Goureевич, and J. H. Arnsten, “Effects of methadone on QT-interval dispersion,” Pharmacotherapy, vol. 25, no. 11, pp. 1523–1529, 2005.

[51] D. Medenwald, J. A. Kors, H. Lopponow et al., “Inflammation and prolonged QT time: results from the Cardiovascular Disease, Living and Ageing in Halle (CARLA) study,” PLoS One, vol. 9, no. 4, article e95994, 2014.

[52] Z. X. Shen, G. Q. Chen, J. H. Ni et al., “Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients,” Blood, vol. 89, no. 9, pp. 3354–3360, 1997.

[53] C. Niu, H. Yan, T. Yu et al., “Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients,” Blood, vol. 94, no. 10, pp. 3315–3324, 1999.

[54] D. Unnikrishnan, J. P. Dutcher, N. Varshneya et al., “Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide,” Blood, vol. 97, no. 5, pp. 1514–1516, 2001.

[55] K. Ohnishi, H. Yoshida, K. Shigeno et al., “Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia,” Annals of Internal Medicine, vol. 133, no. 11, pp. 881–885, 2000.

[56] R. R. Shah, J. Morganroth, and D. R. Shah, “Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval),” Drug Safety, vol. 36, no. 5, pp. 295–316, 2013.

[57] C. S. Tam, H. Kantarjian, G. García-Manero et al., “Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia,” Blood, vol. 112, no. 3, pp. 516–518, 2008.

[58] Z. Lu, C. Y. Wu, Y. P. Jiang et al., “Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome,” Sci Transl Med, vol. 4, no. 131, article 131ra50, 2012.

[59] S. N. Holden, S. G. Eckhardt, R. Basser et al., “Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors,” Annals of Oncology, vol. 16, no. 8, pp. 1391–1397, 2005.

[60] S. A. Wells Jr., J. E. Gosnell, R. F. Galg et al., “Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 767–772, 2010.
R. B. Natale, S. Thongprasert, F. A. Greco et al., “Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer,” *Journal of Clinical Oncology*, vol. 29, no. 8, pp. 1059–1066, 2011.

J. Zang, S. Wu, L. Tang et al., “Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis,” *PLoS One*, vol. 7, no. 2, article e30353, 2012.

Lynch DR Jr, J. B. Washam, and L. K. Newby, “QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature,” *Cardiology Journal*, vol. 19, no. 4, pp. 434–438, 2012.

R. L. Pickarz, A. R. Frye, J. J. Wright et al., “Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma,” *Clinical Cancer Research*, vol. 12, no. 12, pp. 3762–3773, 2006.

E. L. Strevel, D. J. Ing, and L. L. Siu, “Molecularly targeted oncology therapeutics and prolongation of the QT interval,” *Journal of Clinical Oncology*, vol. 25, no. 22, pp. 3362–3371, 2007.

T. Nousiainen, E. Vanninen, A. Rantala, E. Jantunen, and J. Hartikainen, “QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin’s lymphoma,” *Journal of Internal Medicine*, vol. 245, no. 4, pp. 359–364, 1999.

X. K. Liu, A. Katchman, S. N. Ebert, and R. L. Woolsey, “The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 287, no. 3, pp. 877–883, 1998.

S. S. Căsinap, B. Fetică, R. Buiga, C. Căsinap, A. M. Constantin, and A. S. Şovrea, “The prognostic role of EBER in pediatric cancer,” *Romanian Journal of Morphology and Embryology*, vol. 56, no. 4, pp. 1269–1277, 2015.

E. P. Cortes, G. Lutman, J. Wanka et al., “Adriamycin (NSC-123127) cardiotoxicity. A clinicopathologic correlation,” *Cancer Treatment Reports*, vol. 6, pp. 215–225, 1975.

R. L. Larsen, R. I. Jakacki, V. L. Vetter, A. T. Meadows, J. H. Silver, and G. Barber, “Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults,” *The American Journal of Cardiology*, vol. 70, no. 1, pp. 73–77, 1992.

L. Steinherz and P. Steinherz, “Delayed cardiac toxicity from anthracycline therapy,” *Pediatrician*, vol. 18, no. 1, pp. 49–52, 1991.

S. E. Lipshultz, S. D. Colan, R. D. Gelber, A. R. Perez-Atayde, S. E. Sallan, and S. P. Sanders, “Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood,” *The New England Journal of Medicine*, vol. 324, no. 12, pp. 808–815, 1991.

R. B. Weiss, A. J. Grillo-López, S. Marsoni, J. G. Posada Jr., F. Hess, and B. J. Ross, “Amsacrine-associated cardiotoxicity: an analysis of 82 cases,” *Journal of Clinical Oncology*, vol. 4, no. 6, pp. 918–928, 1986.

M. M. Massin, M. F. Dresse, V. Schmitz, C. Hoyoux, J. M. Chantraine, and P. Lepage, “Acute arrhythmogenicity of first-dose chemotherapeutic agents in children,” *Medical and Pediatric Oncology*, vol. 39, no. 2, pp. 93–98, 2002.

D. A. Mulrooney, E. Z. Soliman, M. J. Ehrhardt et al., “Electrocardiographic abnormalities and mortality in aging survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study,” *American Heart Journal*, vol. 189, pp. 19–27, 2017.